한국파마

032300KOSDAQ

53.5 / 100

Reference Date: 2026-09-08

Financial Score16.5 / 40

News Sentiment20.0 / 25

Momentum7.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Slightly up 1.8% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

Hanok Pharma focuses on developing and selling prescription drugs for various disease areas such as the central nervous system and circulatory system through its own R&D. It expands its research in biopharmaceuticals and improved drugs via research centers in Daegu and Uijeongbu. Additionally, the company engages in CMO business, producing solid dosage forms and topical solutions, and is expanding its global market through exports and licensing-out deals.

Number of Employees

284people

Average Salary

67.6M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 15.004.0Point

PBR

1.25Industry Average 1.202.5Point

Higher than industry avg (caution)

ROE

-3.77Industry Average 8.000.0Point

Well below industry avg

Debt Ratio

1.87Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20252.0 / 10 points

Revenue Growth Rate

1.0 / 3

Avg ▲2.7% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼58.8% (2-year basis)

ROE Trend

1.0 / 4

Avg ROE 0.6% (declining, 3yr)

Detailed News Sentiment

2 totalPositive 1Neutral 0Negative 1Average Sentiment Score 80

Negative
김승원이 챙긴 제넨셀…허위자료·임상 중단에 투자 가치도 ‘증발’
한국파마의 주가 급락은 제넨셀의 허위자료 제출과 임상 중단으로 인한 투자 가치 하락에 기인한다.
Positive
한국파마, 상반기 영업이익 35억원… 전년比 280% 성장
한국파마의 상반기 영업이익이 전년 대비 280% 급증하며 큰 성장을 보임.

Detailed Momentum

52-week position1.0Point

Near 52w low (14%, downtrend)

Current 7,890Won52-week high 14,32052-week low 6,800

1-month return3.0Point

1m 1.81% (flat)

Volume trend3.0Point

Volume flat

Detailed Disclosure

2 totalPositive 0Neutral 2Negative 0

Neutral전환사채(해외전환사채포함)발행후만기전사채취득2026-08-28
Neutral반기보고서 (2026.06)2026-08-13